NEXHA DIN 02375176
Health Canada record
| Active ingredient(s) | HYALURONATE SODIUM 10 MG |
|---|---|
| Dosage form | Solution |
| Route | Intra-Articular; Intravenous |
| Schedule | PRESCRIPTION |
| Class | Veterinary |
| ATC | |
| Original market date | 12-Nov-2012 |
| Current status date | 22-Sep-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Vetoquinol N A Inc. — licence 100448, currently licensed, last inspection rating C (2025-10-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing HYALURONATE SODIUM
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02238566 | HY-50 | DECHRA LTD | Solution | HYALURONATE SODIUM 17 MG | Marketed |
| 02169541 | LEGEND | BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC. | Solution | HYALURONATE SODIUM 10 MG | Marketed |
| 02555018 | LEGEND MULTI DOSE | BOEHRINGER INGELHEIM ANIMAL HEALTH CANADA INC. | Solution | HYALURONATE SODIUM 10 MG | Marketed |
| 02254034 | ENHANCE I.A. | VETOQUINOL N A INC | Solution | HYALURONATE SODIUM 10 MG | Cancelled Post Market |
| 02229466 | EQURON | SOLVAY ANIMAL HEALTH, INC. | Liquid | HYALURONATE SODIUM 5 MG | Cancelled (Unreturned Annual) |
| 02194384 | HY-50 INJECTION | GP ASSOCIATES, INC. | Liquid | HYALURONATE SODIUM 17 MG | Cancelled Post Market |
| 00710164 | HYALOVET 20 | VETOQUINOL N A INC | Solution | HYALURONATE SODIUM 10 MG | Cancelled Post Market |
| 02091240 | HYLARTIL VET | ZOETIS CANADA INC | Solution | HYALURONATE SODIUM 10 MG | Cancelled Post Market |
| 02154447 | HYLARTIL VET - LIQ IA 10MG/ML | LUITPOLD PHARMACEUTICALS INC | Liquid | HYALURONATE SODIUM 10 MG | Cancelled Post Market |
| 00791660 | HYONATE 10MG/ML | BAYVET, DIVISION OF CHEMAGRO LTD. | Liquid | HYALURONATE SODIUM 10 MG | Cancelled Post Market |
| 00633801 | SYNACID INJ 10MG/ML | SCHERING-PLOUGH CANADA INC | Liquid | HYALURONATE SODIUM 10 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 26171 | 2021-06-29 | Supplement to an Abbreviated New Drug Submission (SANDS) | Addition of a drug product manufacturing site; Changes to shelf life |
| 16028 | 2014-09-04 | Abbreviated New Drug Submission (ANDS) | TRANSFER OF DRUG IDENTIFICATION NUMBER (DIN) HOLDER |
| 12730 | 2011-10-25 | Abbreviated New Drug Submission (ANDS) |
International API supply for HYALURONATE SODIUM
0 active FDA Drug Master Files.
Request a quote for NEXHA